THE WHAT? 9 members of the US Congress have written to Revlon Group Holdings CEO Michelle Peluso in search of solutions following an FDA warning over testing and quality-control deficiencies on the firm’s Oxford, North Carolina manufacturing facility.
THE DETAILS The congressional letter, led by Consultant Yvette D. Clarke, follows a June FDA warning letter that recognized important Present Good Manufacturing Observe violations involving Revlon’s OTC drug manufacturing. The FDA stated Revlon had not demonstrated satisfactory testing of incoming talc for asbestos and recognized deficiencies in its specs and quality control, together with microbiological requirements for yeast and mildew. The company requested testing of affected talc or completed merchandise, a threat evaluation and a remediation plan. The lawmakers raised explicit considerations about potential publicity amongst Black girls and ladies, citing their important participation within the US magnificence and private care market.
THE WHY? The congressional intervention will increase regulatory and political scrutiny of Revlon’s manufacturing and ingredient-testing controls, highlighting the significance of provider verification, contaminant testing and sturdy high quality methods for cosmetics firms manufacturing OTC magnificence and private care merchandise within the US.
Supply: clarke.home
